STAT+: PTC’s Duchenne muscular dystrophy drug achieves study goal, potentially confirming European approval

PTC Therapeutics said Tuesday that its treatment for Duchenne muscular dystrophy slowed the loss of muscle function in patients in a randomized clinical trial designed to keep the drug on the market in Europe.

But a separate analysis of the same study data that might allow PTC to seek approval in the U.S. failed to reach statistical significance.

Continue to STAT+ to read the full story…